Congenital Disorder of Glycosylation IId: \textit{B4GALT1} Gene Deletion/Duplication

\textbf{Test Code:} DB4GA  
\textbf{Turnaround time:} 2 weeks  
\textbf{CPT Codes:} 81228 x1

\begin{table}[h]
\centering
\begin{tabular}{|l|}
\hline
\textbf{Condition Description} \\
\hline
Congenital disorders of glycosylation (CDG) are a group of autosomal recessive genetic disorders caused by the alteration in synthesis and structure of protein and lipid glycosylation. In the past decade, over 30 genetic diseases have been identified that alter glycan synthesis, structure and ultimately the function of nearly all organ systems.  
\hline
CDG type I (CDGI) disorders result from impaired synthesis of the incomplete lipid linked oligosaccharide (LLO) and/or its attachment to the growing polypeptide chain. CDG-Ia is the most common form reported, due to phosphomannomutase deficiency, an enzyme that converts mannose-6-phosphate to mannose-1-phosphate. CDG-Ib (phosphomannose isomerase, MPI deficiency) is the only known treatable form, by giving mannose orally. CDG type II (CDGII) includes defects in processing of N-glycans.  
\hline
Phenotypes of this disorder are extremely variable. Manifestations range from severe developmental delay and hypotonia with multiple organ system involvement beginning in infancy, to hypoglycemia and protein-losing enteropathy with normal development. Most subtypes have been described in only a few individuals, however, thus understanding of the phenotypes is limited.  
\hline
The current diagnostic test for CDG is analysis of serum transferrin glycoforms, also called "transferrin isoforms analysis", or "carbohydrate-deficient transferrin analysis." If positive, this testing can be followed by DNA testing to identify mutations in the gene involved.  
\hline
One individual has been described with CDG IId. He had mild psychomotor retardation, Dandy-Walker malformation, progressive hydrocephalus, coagulation abnormalities, and elevated serum creatine kinase concentration. In addition, he had muscular hypotonia and myopathy.  
\hline
This affected individual was found to have two mutations in the \textit{B4GALT1} gene (9p13).  
\hline
For patients with suspected CDG IId, sequence analysis is recommended as the first step in mutation identification. For patients in whom mutations are not identified by full gene sequencing, deletion/duplication analysis is appropriate.  
\hline
\textbf{References:}  
\begin{itemize}
\end{itemize}  
\end{tabular}
\end{table}

\textbf{Genes}  
\textit{B4GALT1}

\begin{table}[h]
\centering
\begin{tabular}{|l|}
\hline
\textbf{Indications} \\
\hline
This test is indicated for:  
\begin{itemize}
\item Confirmation of a clinical/biochemical diagnosis of CDG IId in an individual in whom sequence analysis was negative  
\item Carrier testing in adults with a family history of CDG IId in whom sequence analysis was negative  
\end{itemize}  
\end{tabular}
\end{table}

\begin{table}[h]
\centering
\begin{tabular}{|l|}
\hline
\textbf{Methodology} \\
\hline
DNA isolated from peripheral blood is hybridized to a CGH array to detect deletions and duplications. The targeted CGH array has overlapping probes which cover the entire genomic region.  
\hline
\textbf{Detection} \\
\hline
Detection is limited to duplications and deletions. The CGH array will not detect point or intronic mutations. Results of molecular analysis must be interpreted in the context of the patient's clinical and/or biochemical phenotype.  
\hline
\textbf{Specimen Requirements} \\
\hline
\textit{Submit only 1 of the following specimen types}  
\begin{itemize}
\item Type: DNA, Isolated  
\end{itemize}  
\end{tabular}
\end{table}

Disclaimer: This information is confidential and subject to change without notice. It may not be reproduced in whole or part unless authorized in writing by an authorized EGL representative.
Microtainer
3µg
Isolation using the Perkin Elmer™ Chemagen™ Automated Extraction method or Qiagen™ Puregene kit for DNA extraction is recommended.

**Specimen Collection and Shipping:**
Refrigerate until time of shipment in 100 ng/µL in TE buffer. Ship sample at room temperature with overnight delivery.

**Type: Whole Blood (EDTA)**

**Specimen Requirements:**
EDTA (Purple Top)
Infants and Young Children (2 years of age to 10 years old): 3-5 ml
Older Children & Adults: 5-10 ml
Autopsy: 2-3 ml unclootted cord or cardiac blood

**Specimen Collection and Shipping:**
Ship sample at room temperature for receipt at EGL within 24 hours of collection. Do not refrigerate or freeze.

**Special Instructions**
Submit copies of diagnostic biochemical test results with the sample, if appropriate. Contact the laboratory if further information is needed.

Sequence analysis is required before deletion/duplication analysis by targeted CGH array. If sequencing is performed outside of EGL Genetics, please submit a copy of the sequencing report with the test requisition.

**Related Tests**
- Sequence analysis of the B4GALT1 gene is available and is required before deletion/duplication analysis.
- Analysis of other CDG genes is also available.
- Biochemical carbohydrate deficient transferrin analysis for CDGs is also available.
- **Custom diagnostic mutation analysis (KM)** is available to family members if mutations are identified by targeted mutation testing or sequencing analysis.
- Prenatal testing is available to adult couples who are confirmed carriers of mutations. Please contact the laboratory genetic counselor to discuss appropriate testing prior to collecting a prenatal specimen.